ImprimisRx Announces Supply Agreement with EyeCare Services Partners - Seite 3

No ImprimisRx compounded formulation is FDA-approved. Other than drugs compounded at a registered outsourcing facility, all ImprimisRx compounded formulations require a prescription for an individually identified patient consistent with federal and state laws.

Investor Contact:
Jon Patton
[e-mail]
858-704-4587

Media Contact:
Deb Holliday
Holliday Communications, Inc.
[e-mail]
412.877.4519

Contact for EyeCare Services Partners:
Kyle McKinnon
Product Manager – Refractive Marketing
844.ESP.MGMT (844.377.6468)

Source: ImprimisRx and Harrow Health, Inc.